|Chemical and physical data|
|3D model (JSmol)|
Larotrectinib (LOXO-101, ARRY-470) is an experimental drug for the treatment of cancer. It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.
Phase II clinical trials evaluating the drug for efficacy and safety in treating several types of solid tumors are ongoing.
Some clinical trial results were announced in 2017.
- "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL" (PDF). ama-assn.org. October 26, 2016.
- "Larotrectinib". AdisInsight. Retrieved 31 January 2017.
- Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
- Novel Agent Shows Antitumor Activity in TRK-Fusion Cancers. June 2017